Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses ongoing randomized studies of Selinexor and Selinexor with chemotherapy, single-agent activity, etc at the 2017 American Society of Hematology.
Ongoing Randomized Studies of Selinexor – Selinexor with chemotherapy, single-agent activity, etc
